European Urology - Terazosin Modifies the Content of Glycosaminoglycans and the Activity of Matrix Metalloproteinase 2 in the Rat Ventral Prostate
Thursday, 22 February 2007
Volume 51, Issue 2, Pages 447-456 (February 2007)
Abstract -
Objectives:
We have investigated the effects of terazosin on the content of glycosaminoglycans (GAGs), the activity of matrix metalloproteinase 2 (MMP-2) and MMP-9, and the content of tissue inhibitors of MMP (TIMP) in the ventral prostate of Wistar rats.
read more
|
Traditional Foley Drainage Systems—Do They Drain the Bladder?
Monday, 19 February 2007
BERKELEY, CA (UroToday.com) - It is assumed that Foley catheter systems continuously and completely empty the bladder. Beside observations and tubing manipulation that cause a sudden rush of urine flow suggests otherwise.
read more
|
Effect of 1 mg/day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men with Androgenic Alopecia: A Randomized Controlled Trial
Friday, 16 February 2007
BERKELEY, CA (UroToday.com) - Daily finasteride therapy at the prescribed dose for benign prostatic hyperplasia (5 mg) is known to result in a decrease in serum PSA by 50 percent.
read more
|
European Urology - Voiding Symptom Evaluation: It is Time to Recalibrate
Thursday, 15 February 2007
Volume 51, Issue 2, Pages 302-303 (February 2007) Those of us who care for men (and women) who have voiding symptoms are swept by the conundrum of distinguishing quantity from quality. Over the past 20 yr, various symptoms scores such as the Madsen-Iversen, International Prostate Symptom Score (IPSS), and Danish Prostatic Symptom Score (DAN-PSS-1) have focused on quantifying symptoms.
read more
|
European Urology - Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia
Wednesday, 14 February 2007
Volume 51, Issue 2, Pages 524-533 (February 2007) Abstract - Objective:This prospective study quantified cytokine and chemokine levels in seminal plasma of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH), to evaluate inflammatory mediators as possible surrogate markers for diagnosis and treatment efficacy.
read more
|
European Urology - Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire
Friday, 09 February 2007
Volume 51, Issue 2, Pages 473-478 (February 2007) 1. IntroductionA fundamental goal for developing scoring systems for lower urinary tract symptoms (LUTS) has been a need to quantify subjective symptoms of benign prostatic hyperplasia (BPH) and find objective support for the prostatic surgery decision-making.
read more
|
Severe Form of “Enlarged Prostate” Disease Discovered
Wednesday, 07 February 2007
BERKELEY, CA (Newswise) - — Millions of middle-aged and older men experience the symptoms of an enlarged prostate multiple times during the day and night.
read more
|
European Urology - Detection of Escherichia coli 16S RNA and Cytotoxic Necrotizing Factor 1 Gene in Benign Prostate Hyperplasia
Wednesday, 07 February 2007
Volume 51, Issue 2, Pages 457-463 (February 2007) Abstract - Objectives: Inflammation and occasionally necrosis is observed in the prostate tissue from patients with benign prostate hyperplasia (BPH). The etiology of prostatic inflammation/necrosis is unknown, but bacteria may be involved.
read more
|
Watson Announces Positive Phase 3 Study Results on Silodosin for Treatment of Benign Prostatic Hyperplasia
Wednesday, 17 January 2007
CORONA, CA (PRESS RELEASE) - Jan. 16 - Statistical Significance Reached on Primary and Secondary Endpoints
read more
|
BPH & Male LUTS 
